U. S. Aid Shift Sparks Risk of Medicine Shortages in Africa and Asia

The United States is overhauling how it sends life‑saving medicines for HIV and malaria to poorer nations—a change that could leave many countries without essential drugs.

Background

• Until 2016, U.S. donations were managed by the Global Health Supply Chain, run by private firm Chemonics.
• Over $5 billion in medicines were shipped to 90 countries, mainly in sub‑Saharan Africa and Asia.

Trump’s Aid Freeze

• President Trump halted all international aid in January 2024.
• Supplies—including HIV treatments and insecticide‑treated bed nets—were stranded in ports and warehouses.
• A later waiver returned some products, but the program’s future remained uncertain.

Immediate Risks

• The State Department warned U.S. staff in 17 African countries and Haiti to stop the current supply program by May 30.
• Chemonics’ contract ended on September 30, with official termination slated for November.
• The email highlighted “immediate risks to service continuity” if the transition is rushed, yet offered no clear plan.

Potential Alternatives

• Discussions are underway with the Global Fund to Fight AIDS, Tuberculosis and Malaria to use its supply platform for future deliveries.
• The Global Fund already purchases ~$2 billion a year of health products and runs an online procurement system.
• Experts caution that the proposed November 2027 transition is unrealistic, as ordering and delivering medicines to remote areas can take up to a year.

Shift Toward Bilateral Agreements

• The “America First” health strategy aimed to cut contractor use, claiming such firms add waste.
• Washington is moving toward bilateral agreements with recipient governments and private logistics companies.
• Direct funding has been pledged to Kenya, Rwanda, Uganda, and Zambia—though negotiations remain in flux.
• In Kenya, a court challenge over data privacy is delaying the deal.
• Talks with Zambia have stalled.

Bottom Line

The U.S. shift toward a new aid model risks disrupting access to critical HIV and malaria treatments for millions of people in low‑income regions.